Pharmaceuticals South Africa

South Africa Hepatitis B Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

South Africa Hepatitis B Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

South Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $22.0 Mn Placeholder estimate
Estimate 2025 $23.3 Mn 0.7% of the global market
Projected 2034 $37.7 Mn 61.9% Adds $14.4 Mn over 9 forecast years
CAGR 2025–2034 5.5% Faster than 10% of 186 Pharmaceuticals markets here
Key players 5
  • South Africa is 0.72% of the global market.
  • In Africa, the largest is South Africa (this report) at $23.3 Mn.
  • Fastest growing: South Africa (this report) at 5.5% a year.
  • South Africa ranks 1st of 3 by size in Africa.

Market size projection

South Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$14.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hepatitis B Treatment Market market size by year, South Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $22.0 Mn — —
2025 (base) $23.3 Mn +$1.2 Mn —
2026 (forecast) $24.5 Mn +$1.3 Mn +5.5%
2027 (forecast) $25.9 Mn +$1.3 Mn +11.3%
2028 (forecast) $27.3 Mn +$1.4 Mn +17.4%
2029 (forecast) $28.8 Mn +$1.5 Mn +23.9%
2030 (forecast) $30.4 Mn +$1.6 Mn +30.7%
2031 (forecast) $32.1 Mn +$1.7 Mn +37.9%
2032 (forecast) $33.8 Mn +$1.8 Mn +45.5%
2033 (forecast) $35.7 Mn +$1.9 Mn +53.5%
2034 (forecast) $37.7 Mn +$2.0 Mn +61.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

South Africa Hepatitis B Treatment Market Analysis at a glance
Market size, 2025$23.3 Mn placeholder estimate
Forecast, 2034$37.7 Mn placeholder estimate
Growth (CAGR), 2025–20345.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledHepatitis B Therapeutics
SegmentsDrug class, type and end user (see all)
Key playersGilead Sciences, Inc., GSK PLC, Arbutus Biopharma, Vir Biotechnology, Roche (see all)
Regulator in South AfricaSAHPRASource: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
Active clinical trials4 in South AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The South Africa Hepatitis B Treatment Market Analysis Executive Summary

Hepatitis B treatments control a long-term liver virus to prevent cirrhosis and liver cancer, and new drugs aim for a functional cure.

Key segments of the hepatitis B Treatment market include drug class (Nucleos(t)ide Analogs, Interferons and Pipeline (Functional Cure)) and type (Chronic Hepatitis B and Hepatitis B and D Coinfection).

Bar chart: South Africa Hepatitis B Treatment market size, 2024–2034, placeholder estimates. $22.0 Mn in 2024, $23.3 Mn in 2025 and $37.7 Mn in 2034, 5.5% CAGR.
South Africa Hepatitis B Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

South Africa Hepatitis B Treatment Market Dynamics

Market Growth Drivers

Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the hepatitis B Treatment market.

Opportunity

Microbiome-based treatments, earlier testing and digital gut-health programmes give the hepatitis B Treatment market room to grow.

Market Restraints

Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the hepatitis B Treatment market.

Competitive Landscape for Hepatitis B Treatment Market in South Africa

The hepatitis B Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hepatitis B Treatment Market in South Africa

Hepatitis B Treatment in South Africa: rules, payment and research

The South African Health Products Regulatory Authority (SAHPRA) registers medicines.⁠[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.⁠[2] ClinicalTrials.gov lists 4 studies on Hepatitis B Treatment that are recruiting, active or about to start in South Africa.⁠[3]

[1] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[2] National Department of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hepatitis B Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in South Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hepatitis B Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hepatitis B Treatment in context

South Africa compared

  • Health spending per person: 537 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.79 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 6.9% of people (2025). World: 10.4% of people (2025). 2nd highest of the 17 countries we cover in Africa.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Hepatitis B Treatment market in South Africa?
Placeholder estimate: about $23.3 Mn in 2025, rising to about $37.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Hepatitis B Treatment market in South Africa growing?
Placeholder estimate: about 5.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Hepatitis B Treatment market report cover?
The report splits the market by drug class (Nucleos(t)ide Analogs, Interferons, Pipeline (Functional Cure)), type (Chronic Hepatitis B, Hepatitis B and D Coinfection) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Hepatitis B Treatment market?
Key players include Gilead Sciences, Inc., GSK PLC, Arbutus Biopharma, Vir Biotechnology and Roche.
What is driving the Hepatitis B Treatment market?
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the hepatitis B Treatment market.
Who regulates Hepatitis B Treatment in South Africa?
The South African Health Products Regulatory Authority (SAHPRA) registers medicines. Source: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
How is healthcare paid for in South Africa?
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone. Source: National Department of Health. Checked 14 Nov 2026.
How many clinical trials on Hepatitis B Treatment are running in South Africa?
4 studies are recruiting, active or about to start in South Africa, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
How much research is published on Hepatitis B Treatment?
PubMed lists 121 papers on Hepatitis B Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in South Africa

See all

Related on hepatitis and liver health

See the topic